With snowballing healthcare spending and the emergence of new modalities of treatments, discussions are heating up around revisiting the scope of health coverage on pharmaceuticals, with the Ministry of Finance (MOF) and payers advocating the mantra of “large risks with…
HOME > ACADEMIA
ACADEMIA
- MHLW Study Group Aims to Formulate Guidelines for Treatment of Skeletal Dysplasias in FY2017
June 29, 2016
- Nexium, Takecab Added to Standard Treatments for 1st Eradication of H. Pylori: JSHR Guidelines
June 28, 2016
- PD-1’s “Actual Physiology Remains Unclear”: Discoverer of PD-1
June 21, 2016
- No Increased Mortality Risks Seen in Japanese AD Patients on Antipsychotics: Study
June 17, 2016
- Victoza 1st GLP-1 Agent to Thwart Cardiovascular Events; Will It Catch on?
June 15, 2016
- Academic Societies Drafting Guidelines for Clinically Evaluating Efficacy of Drugs for AMR Infectious Diseases
June 15, 2016
- As Spate of Melanoma Drugs Debut, Physicians Still Exploring Best Drug Choices, Combos
June 14, 2016
- Gilead’s 2 Hep C Treatments Highly Effective in Actual Clinical Practice: Multicenter Studies Results
May 24, 2016
- Diabetes Society Calls for Careful Administration of SGLT-2 Inhibitors to Geriatric Syndrome Patients, Aged 75 or Over
May 19, 2016
- MHLW Study Group Drafting Guidelines for Assessing Cost-Effectiveness of Vaccines Proposed for Inclusion in Public Vaccination Programs
May 16, 2016
- Use Patient Registries for Orphan, Intractable Diseases First: MHLW Study Group Chief
May 9, 2016
- At Least 20% of Patients Taking Xeljanz against Guidelines: Interim Analysis of PMS
April 26, 2016
- AMED Study Team Drafting First Guidelines for Diagnosis and Treatment of Post-Stroke Epilepsy
April 21, 2016
- 17 Japanese Medical Societies Jointly Recommend HPV Vaccines
April 20, 2016
- Positioning of Abraxane and Anti-PD-1 Antibodies Will Be Focus of Interest in Revised Guidelines for Gastric Cancer
March 23, 2016
- It’s Time to Discuss Restart of HPV Vaccine Promotion, Panel Chief Says as Personal View
March 16, 2016
- Biomarkers Urgently Needed to Tackle Ballooning Immunotherapy Costs: Oncologist
March 15, 2016
- Japan’s First Diabetes Management Guidelines for Elderly to Be Announced in May
March 11, 2016
- Development of AT2 Receptor-Related New Drugs Forging Ahead Overseas, but Japan Is “Far Behind”
February 22, 2016
- Sanofi, Univ. of Tokyo Form Strategic Partnership on Drug Discovery Research
February 19, 2016
ページ
As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In my home country of Australia, there is a famous candy called “Minties”. Minties has a long-running advertising campaign, presenting comical situations, with the caption, “It’s moments like these.” The phase has become part of the Aussie vernacular, meaning in…